REG - Venture Life Group - Director/PDMR Shareholding

Venture LifeAnnouncement

30/10/2024 12:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241030:nRSd2610Ka&default-theme=true

RNS Number : 2610K  Venture Life Group PLC  30 October 2024

30 October 2024

 

 

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Group")

 

Director/PDMR Shareholding

 

Venture Life (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the international self-care market, announces
that Paul McGreevy, Non-Executive Chairman, has today purchased 116,519
ordinary shares of 0.3p each in the Company ("Ordinary Shares") at a price of
42.9 pence per Ordinary Share.

 

Following this purchase, Mr McGreevy beneficially holds 806,385 Ordinary
Shares representing approximately 0.63 per cent. of the Company's issued share
capital.

 

For further information, please contact:

 

 Venture Life Group PLC                                    +44 (0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Daniel Wells, Chief Financial Officer

 Cavendish Capital Markets Limited (Nomad and Broker)      +44 (0) 20 7397 8900
 Michael Johnson (Sales)

 Stephen Keys / Camilla Hume (Corporate Finance)

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, Italy, The Netherlands and
Sweden, the Group's product portfolio includes some key products such as the
UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the
area of women's intimate healthcare, the Lift and Glucogel product ranges for
hypoglycaemia, Gelclair and Pomi-T for oncology support, Earol for ear wax
removal, products for fungal infections and proctology, and dermo-cosmetics
for addressing the signs of ageing. Its products are sold in over 90 countries
worldwide.

 

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK and The Netherlands these are supplied direct by the
Company to retailers, elsewhere they are supplied by the Group's international
distribution partners.

 

Through its two Development & Manufacturing operations in Italy and
Sweden, the Group also provides development and manufacturing services to
companies in the medical devices and cosmetic sectors.

 

 

The Company makes the following disclosures in accordance with article 19(3)
of the Market Abuse Regulation:

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Paul McGreevy

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Chairman

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Venture Life Group plc

 b)   LEI                                                          213800S8CZUPLAB2KC70

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.3p each in Venture Life Group plc

      Identification code

                                                                   GB00BFPM8908
 b)   Nature of the transaction                                    Purchase of ordinary shares

 c)   Price(s) and volume(s)                                       Price  Volume

                                                            42.9p  116,519

 d)   Aggregated information                                       n/a

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      30 October 2024

 f)   Place of the transaction                                     London Stock Exchange

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

n/a

 

 

 

 

 

 

 

e)

 

Date of the transaction

 

30 October 2024

f)

 

Place of the transaction

 

London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFIFIILIVIS